ProQR Therapeutics NV priced an underwritten public offering of 5,750,000 ordinary shares at $15.75 each.
The Netherlands-based biopharmaceutical company expects to raise gross proceeds of about $90.6 million through the offering, which is expected to close Sept. 11, subject to customary closing conditions.
Underwriters have a 30-day option to buy up to 862,500 additional ordinary shares at the offering price.
Citigroup, Evercore ISI and RBC Capital Markets are acting as joint book runners for the offering, with H.C. Wainwright & Co. and Chardan as co-managers. Kempen & Co. is acting as ProQR's European financial adviser for the offering.